News
02-07-2012, 07:50 PM
U.S. health regulators, the Food and Drugs Administration (FDA) has granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. Pertuzumab approval decision is due by June 8th this year. It could be used with Herceptin in HER2-positive patients. This was announced by Roche Holding AG's Genentech unit on Tuesday.
More... (http://www.news-medical.net/news/20120207/Rochee28099s-new-breast-cancer-drug-Pertuzumab-up-for-FDA-review.aspx)
More... (http://www.news-medical.net/news/20120207/Rochee28099s-new-breast-cancer-drug-Pertuzumab-up-for-FDA-review.aspx)